Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2025-521827-61-00
Authorised, not yet recruiting Phase II

Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125

2025-521827-61-00 · tracked via the Priya Life Science EU tracker
Sponsor
Fondazione Gimema Franco Mandelli Onlus
Sponsor type
Patient organisation/association
Therapeutic area
Hemic and Lymphatic Diseases
Decision date
14/04/2026
Enrollment target
52
Sites
Italy

Condition studied

refractory/relapsed multiple myeloma

Investigational medicinal product(s)

TECLISTAMAB

Every trial of Teclistamab across our registers →

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Estimation of the DoR at 18 months from the combination therapy (24 months from the beginning of Te monotherapy).

Endpoint detail

Response at cycles 5 and every 3 cycles according to the IMWG criteria (15), PFS at 18 months from beginning of therapy with Te and ALI, Overall Survival at 24 months from the beginning of therapy with Te, Safety profile overall and with a focus on CRS according to ASTCT (16) and ICANS according to ASTCT (16)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521827-61-00 on CTIS ↗ ← All trials in the EU